Literature DB >> 22527383

[Onychomycosis with onychodystrophy or acrolentiginous melanoma with onychomycosis and onychodystrophy?].

A Blum1.   

Abstract

A 68-year-old female patient had been treated locally and systemically for onychomycosis of the left thumbnail for 1 year. During the course of treatment there was increasing destruction of approximately 50% of the nail without Hutchinson's sign. Dermoscopically there were yellow to brown vertical stripes of varying width in the remaining parts of the nail. In the visible nail matrix reddish, brownish and grey-black colored components with varying differential structures could be detected. An acrolentiginous melanoma with a diameter of 1.04 mm could be identified histologically and the associated onychomycosis was confirmed by culturing.

Entities:  

Mesh:

Year:  2012        PMID: 22527383     DOI: 10.1007/s00105-012-2347-6

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  4 in total

Review 1.  Conservative surgical management of subungual (matrix derived) melanoma: report of seven cases and literature review.

Authors:  N Sureda; A Phan; N Poulalhon; B Balme; S Dalle; L Thomas
Journal:  Br J Dermatol       Date:  2011-08-04       Impact factor: 9.302

2.  Key point in dermoscopic differentiation between early nail apparatus melanoma and benign longitudinal melanonychia.

Authors:  Hiroshi Koga; Toshiaki Saida; Hisashi Uhara
Journal:  J Dermatol       Date:  2011-01       Impact factor: 4.005

3.  Dermoscopic examination of nail pigmentation.

Authors:  Sandra Ronger; Sandrine Touzet; Claire Ligeron; Brigitte Balme; Anne Marie Viallard; Danièle Barrut; Cyrille Colin; Luc Thomas
Journal:  Arch Dermatol       Date:  2002-10

4.  [Operative therapy of acral melanomas].

Authors:  M Möhrle; V Lichte; H Breuninger
Journal:  Hautarzt       Date:  2011-05       Impact factor: 0.751

  4 in total
  1 in total

Review 1.  [Dark nail: clinical findings, diagnostics and therapy of melanonychia].

Authors:  C Löser; P A Mayser
Journal:  Hautarzt       Date:  2014-04       Impact factor: 0.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.